Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 5Trastuzumab 4Taxes 4Docetaxel 4Paclitaxel 3Albumin-Bound Paclitaxel 3tipifarnib 2sargramostim 2liposomal doxorubicin 2Vorinostat 2Immunohistochemistry 2Granulocyte-Macrophage Colony-Stimulating Factor 2Filgrastim 2Enzyme-Linked Immunosorbent Assay 2Doxorubicin 2Capecitabine 2temsirolimus 1seviteronel 1romidepsin 1poly(I).poly(c12,U) 1pertuzumab 1pegfilgrastim 1oblimersen 1ixabepilone 1interferon gamma-1b 1flt3 ligand protein 1denileukin diftitox 1cixutumumab 1alvocidib 1Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms, Male × poly(I).poly(c12,U) × Clear all
NCT01355393 2020-02-10

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

University of Washington

Phase 1/2 Completed
50 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡